Market Movers Today: Arcadia Biosciences Inc (RKDA), Signet Jewelers Ltd. (SIG), Adidas AG (ADR) (ADDYY), Daxor Corporation (DXR), and More

Page 1 of 2

Arcadia Biosciences Inc (NASDAQ:RKDA) (MarketWatch)
Shares of Arcadia Biosciences Inc. RKDA, +237.05% an agricultural biotech that seeks to develop products that benefit the environment and human health, extended early gains to trade up 260% on Wednesday after the company announced that it has reached two key milestones in its High Fiber Resistant Starch Wheat program. The stock has been on a run for the last week, although there was no apparent news driving the move. The company has a market capitalization of just $72 million with today’s rally, according to FactSet data.

Signet Jewelers Ltd. (NYSE:SIG) (The Motley Fool)
What happened: Shares of Signet Jewelers Ltd. (NYSE:SIG) were losing their luster today after the jewelry seller posted underwhelming fourth-quarter results and announced a three-year restructuring plan. The shift comes as the parent of Kay, Jared, Zales, and other retail jewelry chains continues to lose sales as mall traffic declines. The stock was down 16.8% as of 10:51 a.m. EST.

stocks, analysis, market, numbers, business, ticket, trade, money, price


adidas AG (ADR) (OTCMKTS:ADDYY) (Reuters)
HERZOGENAURACH, Germany (Reuters) – Shares in German sportswear firm Adidas (ADSGn.DE) soared on Wednesday after it announced a big buyback, gave an upbeat outlook for 2018 and lifted its 2020 profitability forecast, while conceding it would be hard to match rival Nike’s margins. Adidas said late on Tuesday it plans to buy back up to 3 billion euros ($3.7 billion) of its shares, or almost 9 percent of its share capital, by 2021 on top of a higher-than-expected 2017 dividend of 2.60 euros per share. The company’s online sales leaped 57 percent in 2017 to 1.5 billion euros, or about 7 percent of sales.

Daxor Corporation (NYSEAMERICAN:DXR) (Benzinga)
Daxor Corporation gained 44.1 percent to $7.25 after report of data showing patient care individualized by Daxor’s precision blood volume analysis reduced heart failure readmissions by 56% and mortality by 80%.

Page 1 of 2